BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36257585)

  • 41. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
    Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
    Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
    Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
    Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protein-coding genes combined with long non-coding RNAs predict prognosis in esophageal squamous cell carcinoma patients as a novel clinical multi-dimensional signature.
    Guo JC; Li CQ; Wang QY; Zhao JM; Ding JY; Li EM; Xu LY
    Mol Biosyst; 2016 Oct; 12(11):3467-3477. PubMed ID: 27714034
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
    Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
    Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. miR-378a-5p exerts tumor-suppressive effects on esophageal squamous cell carcinoma after neoadjuvant immunotherapy by downregulating APOC1/CEP55.
    Pengjie Y; Rong J; Pengfei N
    Sci Rep; 2024 Jan; 14(1):305. PubMed ID: 38172247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ferroptosis-Related lncRNA Signature Correlates with the Prognosis, Tumor Microenvironment, and Therapeutic Sensitivity of Esophageal Squamous Cell Carcinoma.
    Zhu J; Zhao Y; Wu G; Zhang X; Chen Q; Yang B; Guo X; Ji S; Gu K
    Oxid Med Cell Longev; 2022; 2022():7465880. PubMed ID: 35903713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy.
    Wen J; Luo K; Liu H; Liu S; Lin G; Hu Y; Zhang X; Wang G; Chen Y; Chen Z; Li Y; Lin T; Xie X; Liu M; Wang H; Yang H; Fu J
    Ann Surg; 2016 May; 263(5):942-8. PubMed ID: 26445467
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.
    Han D; Han Y; Guo W; Wei W; Yang S; Xiang J; Che J; Zhu L; Hang J; van den Ende T; van Laarhoven HWM; Li B; Ye Y; Li H
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38016720
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel and robust pyroptosis-related prognostic signature predicts prognosis and response to immunotherapy in esophageal squamous cell carcinoma.
    Zhang D; Zhao F; Li J; Qin X; Li S; Niu R
    Aging (Albany NY); 2023 Aug; 15(15):7811-7830. PubMed ID: 37561524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma.
    Qu J; Zhao Q; Yang L; Ping Y; Zhang K; Lei Q; Liu F; Zhang Y
    Int Immunopharmacol; 2021 Jul; 96():107616. PubMed ID: 34162127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computed tomography-based deep-learning prediction of neoadjuvant chemoradiotherapy treatment response in esophageal squamous cell carcinoma.
    Hu Y; Xie C; Yang H; Ho JWK; Wen J; Han L; Lam KO; Wong IYH; Law SYK; Chiu KWH; Vardhanabhuti V; Fu J
    Radiother Oncol; 2021 Jan; 154():6-13. PubMed ID: 32941954
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epithelial-Mesenchymal Transition Gene Signature Is Associated with Neoadjuvant Chemoradiotherapy Resistance and Prognosis of Esophageal Squamous Cell Carcinoma.
    Song K; Gu B; Ma C; Wang B; Wang N; Yu R; Chen H
    Dis Markers; 2022; 2022():3534433. PubMed ID: 36072903
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
    Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
    Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
    J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PES1 reduces CD8
    Ma N; Hua R; Yang Y; Liu ZC; Pan J; Yu BY; Sun YF; Xie D; Wang Y; Li ZG
    J Biomed Sci; 2023 Mar; 30(1):20. PubMed ID: 36959575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel long non-coding RNA FOXCUT and mRNA FOXC1 pair promote progression and predict poor prognosis in esophageal squamous cell carcinoma.
    Pan F; Yao J; Chen Y; Zhou C; Geng P; Mao H; Fang X
    Int J Clin Exp Pathol; 2014; 7(6):2838-49. PubMed ID: 25031703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.